96847-55-1

Basic information

• Product Name: Levomilnacipran
• Synonyms: levomilnacipran;(1R,2S)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide;CyclopropanecarboxaMide,2-(aMinoMethyl)-N,N-diethyl-1-phenyl-, (1R,2S)-;Fetzima
• CAS NO: 96847-55-1
• Molecular Formula: C15H22N2O
• Molecular Weight: 246.35
• Product Categories: Inhibitors
• Mol File: 96847-55-1.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 393 °C at 760 mmHg
• Flash Point: 191.5 °C
• Appearance: /
• Density: 1.077
• PKA: 10.36±0.29(Predicted)
• CAS DataBase Reference: Levomilnacipran(CAS DataBase Reference)
• NIST Chemistry Reference: Levomilnacipran(96847-55-1)
• EPA Substance Registry System: Levomilnacipran(96847-55-1)

Safety Data

• Hazardous Substances Data: 96847-55-1(Hazardous Substances Data)

Usage

General Description

Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) medication used to treat major depressive disorder. It works by increasing the levels of serotonin and norepinephrine, two naturally occurring substances in the brain that are believed to be involved in regulating mood and emotion. Levomilnacipran is available in extended-release capsules and should be taken once daily, with or without food. Common side effects may include nausea, dry mouth, constipation, increased heart rate, and increased blood pressure. It is important to consult with a healthcare professional before using levomilnacipran, as it may interact with other medications and medical conditions.

Upstream product

• 105310-75-6 (1R,2R)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-1-phenyl-cyclopropanecarboxylic acid diethylamide 
• 131091-01-5 (1R,2R)-2-Hydroxymethyl-1-phenyl-cyclopropanecarboxylic acid diethylamide 
• 105310-75-6 (1SR,2RS)-2-((1,3-dioxoisoindolin-2-yl)methyl)-N,N-diethyl-1-phenylcyclopropane carboxamide 
• 105310-90-5 (Z)-1-phenyl-2-(bromomethyl)-N,N-diethylcyclopropanecarboxamide 
• 910028-42-1 (1R,2S)-2-Hydroxymethyl-1-phenyl-cyclopropanecarbonitrile 
• 98-80-6 phenylboronic acid 
• 32634-66-5 Di-p-toluoyl-L-tartaric acid 
• 105310-09-6 milnacipran 
• 50583-51-2 O,O′-di-p-anisoyl-D-tartaric acid 
• 86181-08-0 cis-(±)-1-phenyl-2-(aminomethyl)-N,N-diethylcyclopropanecarboxamide hydrochloride 
• 140-29-4 phenylacetonitrile 
• 923037-67-6 Toluene-4-sulfonic acid (1R,2R)-2-diethylcarbamoyl-2-phenyl-cyclopropylmethyl ester 
• 1353644-50-4 1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane 

Downstream Products

• 1418000-39-1 N,N-diethyl-2-methyl-1-phenylcycloprop-2-enecarboxamide 
• 105310-06-3 2-(aminomethyl)-1-phenylcyclopropanecarboxamide 

Relevant articles and documents

Preparation method of milnacipra hydrochloride intermediate

The invention provides a preparation method of an intermediate hydrochloride intermediate. Belong to chemical medicine preparation technical field. To the preparation method, the compound having the structure of the formula (II) is added into the methanol

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.